TheraRadar
Data updated: May 26, 2026

EDETATE CALCIUM DISODIUM

Other Approved 2023-05-03

EDETATE CALCIUM DISODIUM is indicated for the treatment of Lead Poisoning; Lead Encephalopathy.

Source: FDA Label • CASPER PHARMA LLC
1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2023-05-03
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: EDETATE CALCIUM DISODIUM

EDETATE CALCIUM DISODIUM Approval History

2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2023 to 2023
May 2023 ORIGINAL
Update

What EDETATE CALCIUM DISODIUM Treats

2 indications

EDETATE CALCIUM DISODIUM is approved for 2 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Lead Poisoning
  • Lead Encephalopathy
Source: FDA Label

EDETATE CALCIUM DISODIUM Boxed Warning

WARNINGS Edetate calcium disodium injection is capable of producing toxic effects which can be fatal. Lead encephalopathy is relatively rare in adults, but occurs more often in pediatric patients in whom it may be incipient and thus overlooked. The mortality rate in pediatric patients has been high. Patients with lead encephalopathy and cerebral edema may experience a lethal increase in intracranial pressure following intravenous infusion; the intramuscular route is preferred for these patients....

EDETATE CALCIUM DISODIUM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

1

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to EDETATE CALCIUM DISODIUM

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CHEMET
SUCCIMER
1 shared
RECORDATI RARE
Shared indications:
Lead Poisoning
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT03630991 2017-0752 NCI-2018-01610, 2017-0752 Ph 1 recruiting Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
NCT02421029 MRI-EDTA Ph 4 withdrawn Prolonged Gadolinium Retention After MRI Imaging
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EDETATE CALCIUM DISODIUM FDA Label Details

Indications & Usage

EDETATE CALCIUM DISODIUM is indicated for the treatment of Lead Poisoning; Lead Encephalopathy.

⚠️ BOXED WARNING

WARNINGS Edetate calcium disodium injection is capable of producing toxic effects which can be fatal. Lead encephalopathy is relatively rare in adults, but occurs more often in pediatric patients in whom it may be incipient and thus overlooked. The mortality rate in pediatric patients has been high....

Looking for the branded version?

CALCIUM DISODIUM VERSENATE

Full clinical data, patents, trials, and competitive landscape for edetate calcium disodium.

See CALCIUM DISODIUM VERSENATE

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.